CRISPR Therapeutics’ (CRSP) “Market Outperform” Rating Reiterated at JMP Securities

JMP Securities reissued their market outperform rating on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a research note issued to investors on Friday,Benzinga reports. They currently have a $86.00 price target on the stock.

CRSP has been the subject of several other research reports. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research report on Wednesday, December 11th. Needham & Company LLC reiterated a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Chardan Capital reissued a “buy” rating and set a $94.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Royal Bank of Canada restated a “sector perform” rating and issued a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Finally, Barclays dropped their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, CRISPR Therapeutics has a consensus rating of “Hold” and a consensus target price of $77.93.

CRISPR Therapeutics Stock Up 0.8 %

CRSP stock opened at $40.72 on Friday. The stock has a market cap of $3.48 billion, a P/E ratio of -14.39 and a beta of 1.62. The business’s 50-day moving average price is $48.45 and its 200-day moving average price is $50.66. CRISPR Therapeutics has a twelve month low of $39.41 and a twelve month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The firm had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. During the same period last year, the firm posted ($1.41) earnings per share. On average, equities research analysts expect that CRISPR Therapeutics will post -5.13 earnings per share for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the sale, the general counsel now directly owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. This represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Samarth Kulkarni sold 4,293 shares of the firm’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the sale, the chief executive officer now owns 226,540 shares in the company, valued at $10,484,271.20. This represents a 1.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 50,382 shares of company stock valued at $2,744,179. 4.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Large investors have recently made changes to their positions in the business. Larson Financial Group LLC grew its stake in CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after buying an additional 276 shares during the last quarter. Itau Unibanco Holding S.A. acquired a new stake in CRISPR Therapeutics in the second quarter worth about $35,000. Denver PWM LLC purchased a new stake in shares of CRISPR Therapeutics during the second quarter worth about $45,000. National Bank of Canada FI increased its holdings in shares of CRISPR Therapeutics by 35.0% during the second quarter. National Bank of Canada FI now owns 848 shares of the company’s stock valued at $46,000 after acquiring an additional 220 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of CRISPR Therapeutics in the 3rd quarter valued at approximately $40,000. 69.20% of the stock is owned by institutional investors and hedge funds.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.